https://doi.org/10.55788/a4a7b185
Switching between biologicals in patients with severe asthma can be considered in case of poor response to treatment (including exacerbations, symptom control, and lung function), side effects, and if patients are pregnant or breastfeeding. With the increasing number of available products, switching between biologicals will become part of common daily clinical practice and so far, combining type2-targeted biologicals seems safe and effective [1]. With increasing insights, more differentiated treatment algorithms and long-term safety and efficacy evaluations will follow in the near future.
Currently, 5 biologicals are available for the treatment of severe asthma: omalizumab (anti-IgE), mepolizumab, reslizumab, and benralizumab (anti-IL-5/5Rα), and dupilumab (anti-IL-4Rα). Possible switches include switching to another biological with a similar or different mode of action or to combine two different modes of action following case reports showing a good clinical response without safety issues. It is important to check that patients fulfil eligibility criteria for a new biological either on or before the current biological if a switch is considered. Most likely, a wash-out period is not necessary when switching biologicals. It needs to be noted that in earlier days only omalizumab was available; many patients who would have been better candidates for anti-IL-5/5R/4R were treated with omalizumab. Presently, these patients may qualify for switching to another biological (e.g. anti-IL-5/5Rα or anti-IL-4Rα). Regarding benralizumab, this biological induces a more complete depletion of eosinophils than mepolizumab which may offer superior clinical effectiveness in some patients with pronounced eosinophilia. However, this requires close monitoring given the potential downside of eosinophil depletion. Furthermore, physicians need to be aware of possible (often transient) increases in blood eosinophils when patients are switched from anti-IL-5/5R to dupilumab [2].
- Ortega G, et al. Ann Allergy Asthma Immunol. 2019 Sep;123(3):309-311.
- Lehtimäki L. Switching biologics, how and when? Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Targeting treatable traits allows a personalised approach to management of (severe) asthma Next Article
Common comorbidities in severe asthma »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
New antigens in sarcoidosis
Fatigue syndrome in sarcoidosis
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy